PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 76989

Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03982286

Position: Peer Reviewer

Academic degree: N/A

Professional title: N/A

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-05-18 06:52

Reviewer performed review: 2022-05-18 07:09

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[Y] Major revision</td>
</tr>
<tr>
<td></td>
<td>[ ] Rejection</td>
<td>[ ] Rejection</td>
</tr>
</tbody>
</table>

| Re-review          | [ ] Yes                     | [Y] No                   |
SPECIFIC COMMENTS TO AUTHORS
The authors show the N/K lymphoma treated with anti-PD-1 drug. The case is so interesting, however, I have some concerns to be discussed. 1. How about involvement of inflammatory markers such as IL-2, or IFN? Please discuss citing the following article. (2021). Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. European journal of histochemistry: EJH, 65(3), 3203. https://doi.org/10.4081/ejh.2021.3203 2. How do you think about mutual effect between NK cell and PD-1 positive cell? 3. Please show the SUV-max in Figure 1. 4. Please make more enrich the legends in Figure 2.
Name of journal: World Journal of Clinical Cases

Manuscript NO: 76989

Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05776275

Position: Peer Reviewer

Academic degree: PhD

Professional title: Research Associate

Reviewer’s Country/Territory: United Kingdom

Author’s Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-05-25 11:08

Reviewer performed review: 2022-06-02 07:45

Review time: 7 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ Y] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td></td>
<td>[ ] Grade E: Do not publish</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ Y] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ Y] Major revision</td>
</tr>
<tr>
<td></td>
<td>[ ] Rejection</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Re-review</th>
<th>[ ] Yes</th>
<th>[ Y] No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Peer-reviewer statements</th>
<th>Peer-Review: [ Y ] Anonymous  [ ] Onymous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Conflicts-of-Interest: [ ] Yes  [ Y ] No</td>
</tr>
</tbody>
</table>

**SPECIFIC COMMENTS TO AUTHORS**

The authors have demonstrated the efficacy of the combination of decitabine and anti-PD-1. The manuscript lacks introduction (background information is lacking). The abstract lacks detail on the cohort & method.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases
Manuscript NO: 76989
Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 03982286
Position: Peer Reviewer
Academic degree: N/A
Professional title: N/A
Reviewer’s Country/Territory: Japan
Author’s Country/Territory: China
Manuscript submission date: 2022-04-13
Reviewer chosen by: Yu-Lu Chen
Reviewer accepted review: 2022-06-29 03:20
Reviewer performed review: 2022-06-29 03:20
Review time: 1 Hour
Scientific quality  [ ] Grade A: Excellent  [ Y] Grade B: Very good  [ ] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish
Language quality  [ Y] Grade A: Priority publishing  [ ] Grade B: Minor language polishing  [ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection
Conclusion [ Y] Accept (High priority)  [ ] Accept (General priority)
[ ] Minor revision  [ ] Major revision  [ ] Rejection
Peer-reviewer statements

Peer-Review: [Y] Anonymous  [ ] Onymous
Conflicts-of-Interest: [ ] Yes  [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors replied well, so the manuscript is suitable for publication.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases
Manuscript NO: 76989
Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05776275
Position: Peer Reviewer
Academic degree: PhD
Professional title: Research Associate
Reviewer’s Country/Territory: United Kingdom
Author’s Country/Territory: China
Manuscript submission date: 2022-04-13
Reviewer chosen by: Yu-Lu Chen
Reviewer accepted review: 2022-06-29 10:13
Reviewer performed review: 2022-06-30 01:02
Review time: 14 Hours
Scientific quality  [Y] Grade A: Excellent  [ ] Grade B: Very good  [ ] Grade C: Good
SPECIFIC COMMENTS TO AUTHORS

The manuscript demonstrates the potential ability of decitabine combined with PD-1 inhibitor to treat R/R ENKL, thus providing a new treatment strategy.